Table 6.
Predictor | Rate Ratio Based on Full Model | 95% CI | P Value |
---|---|---|---|
Age per 10 years | 1.63 | 1.421, 1.88 | <0.0001 |
Male sex | 1.56 | 1.01, 2.67 | 0.046 |
Year before 1993 | 1.64 | 0.99, 2.63 | 0.053 |
Mean systolic blood pressure per 10-mm Hg increasea | 1.17 | 1.02, 1.35 | 0.022 |
Mean serum cholesterol per 10-mg/dL increasea | 1.04 | 1.01, 1.08 | 0.018 |
Diabetes mellitus | 1.52 | 0.99, 2.33 | 0.057 |
SELENA-SLEDAI per unit increase | 1.05 | 1.00, 1.11 | 0.062 |
Anti-dsDNA present in most recent visit | 1.56 | 1.05, 2.31 | 0.026 |
Serum creatinine, mg/dL | |||
<1.0 | 1.00 | Referent | |
1.0–1.19 | 1.64 | 1.07, 2.50 | 0.023 |
≥1.2 | 1.15 | 0.72, 1.85 | 0.56 |
Low hematocrit | 1.18 | 0.82, 1.69 | 0.38 |
History of hemolytic anemia | 1.28 | 0.79, 2.09 | 0.32 |
History of lupus anticoagulant | 1.74 | 1.22, 2.47 | 0.0021 |
Current corticosteroid dose, mg/day | |||
0 | 1.00 | Referent | |
1–9 | 1.01 | 0.63, 1.60 | 0.98 |
10–19 | 1.47 | 0.90, 2.38 | 0.12 |
≥20 | 2.54 | 1.44, 4.48 | 0.0013 |
Hydroxychloroquine in past 6 consecutive, months | 0.77 | 0.54, 1.12 | 0.17 |
Abbreviations: CI, confidence interval; dsDNA, double stranded DNA; SELENA, Safety of Estrogens in Lupus Erythematosus National Assessment; SLE, systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index instrument score.
a Mean during prior cohort participation.